[1]
|
M. H?ckel, C. Knoop, K. Schlenger, B. Vorndran, E. Baussmann, M. Mitze, P. G. Knapstein and P. Vaupel, “Intratumoral PO2 Predicts Survival in Advanced Cancer of the Uterine Cervix,” Radiotherapy & Oncology, Vol. 26, No. 1, 1993, pp. 45-50.
doi:10.1016/0167-8140(93)90025-4
|
[2]
|
M. H?ckel and P. Vaupel, “Biological Consequences of Tumor Hypoxia,” Seminars in Oncology, Vol. 28, No. 2, 2001, pp. 36-41. doi:10.1016/S0093-7754(01)90211-8
|
[3]
|
B. Movsas, J. D. Chapman, A. L. Hanlon, E. M. Horwitz, R. E. Greenberg, C. Stobbe, G. E. Hanks and A. Pollack, “Hypoxic Prostate/Muscle PO2 Ratio Predicts for Bio- chemical Failure in Patients with Prostate Cancer: Preliminary Findings,” Urology, Vol. 60, No. 4, 2002, pp. 634-639. doi:10.1016/S0090-4295(02)01858-7
|
[4]
|
W. Choi, S. W. Lee, S. H. Park, J. S. Ryu, S. J. Oh, K. C. Im, E. K. Choi, J. H. Kim, S. H. Jung, S. Kim and S. D. Ahn, “Planning Study for Available Dose of Hypoxic Tumor Volume Using Fluorine-18-Labeled Fluoromi-sonidazole Positron Emission Tomography for Treatment of the Head and Neck Cancer,” Radiotherapy & Oncology, Vol. 97, No. 2, 2010, pp. 176-182.
doi:10.1016/j.radonc.2010.04.012
|
[5]
|
I. Toma-Dasu, J. Uhrdin, L. Antonovic, A. Dasu, S. Nuyts, P. Dirix, K. Haustermans and A. Brahme, “Dose Prescription and Treatment Planning Based on FMISO- PET Hypoxia,” Acta Oncologica, Vol. 51, No. 2, 2012, pp. 222-230. doi:10.3109/0284186X.2011.599815
|
[6]
|
K. Hendrickson, M. Phillips, W. Smith, L. Peterson, K. Krohn and J. Rajendran, “Hypoxia Imaging with [F-18] FMISO-PET in Head and Neck Cancer: Potential for Guiding Intensity Modulated Radiation Therapy in Overcoming Hypoxia-Induced Treatment Resistance,” Radiotherapy & Oncology, Vol. 101, No. 3, 2011, pp. 369-375.
doi:10.1016/j.radonc.2011.07.029
|
[7]
|
V. Askoxylakis, J. Dinkel, M. Eichinger, B. Stieltjes, G. Sommer, L. G. Strauss, A. Dimitrakopoulou-Strauss, A. Kopp-Schneider, U. Haberkorn, P. E. Huber, M. Bischof, J. Debus and C. Thieke, “Multimodal Hypoxia Imaging and Intensity Modulated Radiation Therapy for Unre- sectable Non-Small-Cell Lung Cancer: The HIL Trial,” Radiotherapy & Oncology, Vol. 7, No. 1, 2012, pp. 157.
doi:10.1186/1748-717X-7-157
|
[8]
|
B. Wen, M. Urano, J. A. O’Donoghue and C. C. Ling, “Measurements of Partial Oxygen Pressure PO2 Using the OxyLite System in R3327-AT Tumors under Isoflurane Anesthesia,” Radiation Research, Vol. 166, 2006, pp. 512-518. doi:10.1667/RR3602.1
|
[9]
|
B. Wen, M. Urano, J. L. Humm, V. E. Seshan, G. C. Li and C. C. Ling, “Comparison of Helzel and OxyLite Sys- tems in the Measurements of Tumor Partial Oxygen Pressure (PO2),” Radiation Research, Vol. 169, No. 1, 2008, pp. 67-75. doi:10.1667/RR0888.1
|
[10]
|
J. Bussink, J. H. Kaanders and A. J. van der Kogel, “Tu- mor Hypoxia at the Micro-Regional Level: Clinical Relevance and Predictive Value of Exogenous and En- dogenous Hypoxia Cell Markers,” Radiotherapy & Oncology, Vol. 67, No. 1, 2003, pp. 3-15.
doi:10.1016/S0167-8140(03)00011-2
|
[11]
|
C. J. Mathias, M. J. Welch, M. R. Kilbourn, P. A. Jerabek, T. B. Patrick, M. E. Raichle, K. A. Krohn, J. S. Rasey and D. W. Shaw, “Radiolabeled Hypoxia Cell Sensitizers: Tracers for Assessment of Ischemia,” Life Sciences, Vol. 41, No. 2, 1987, pp. 199-206.
doi:10.1016/0024-3205(87)90494-2
|
[12]
|
D. Stypinski, L. I. Wiebe, A. J. McEwan, R. P. Schmidt, Y. K. Tam and J. R. Mercer, “Clinical Pharmacokinetics of 123I-IAZA in Healthy Volunteers,” Nuclear Medicine Communications, Vol. 20, No. 6, 1999, pp. 559-567.
doi:10.1097/00006231-199906000-00011
|
[13]
|
P. E. Volk, C. A. Mathis, M. D. Prados, J. C. Gilbert and T. F. Budinger, “Hypoxia in Human Gliomas: Demon-stration by PET with Fluorine-18-Fluoromisonidazole,” Journal of Nuclear Medicine, Vol. 33, No. 12, 1992, pp. 2133-2137.
|
[14]
|
J. S. Rasey, W. J. Koh, M. L. Evans, L. M. Peterson, T. K. Lewellen, M. M. Graham and K. A. Krohn, “Quanfifying Regional Hypoxia in Human Tumors with Positron Emission Tomography of [18F]Fluoromisonidazole: A Pre- therapy Study of 37 Patients,” International Journal of Radiation Oncology * Biology * Physics, Vol. 36, No. 2, 1996, pp. 417-428. doi:10.1016/S0360-3016(96)00325-2
|
[15]
|
J. G. Rajendran, D. C. Wilson, E. U. Conrad, L. M. Peterson, J. D. Bruckner, J. S. Rasey, L. K. Chin, P. D. Hof-strand, J. R. Grierson, J. F. Eary and K. A. Krohn, “[(18)F]FMISO and [(18)F]FDG PET Imaging in Soft Tissue Sarcomas: Correlation of Hypoxia, Metabolism and VEGF Expression,” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 30, No. 5, 2003, pp. 695-704. doi:10.1007/s00259-002-1096-7
|
[16]
|
F. Dehdashti, P. W. Grigsby, M. A. Mintun, J. S. Lewis, B. A. Siegel and M. J. Welch, “Assessing Tumor Hypoxia in Cervical Cancer by Positron Emission Tomo- graphy with 60Cu-ATSM: Relationship to Therapeutic Response—A Preliminary Report,” International Journal of Radiation Oncology * Biology * Physics, Vol. 55, No. 5, 2003, pp. 1233-1238.
doi:10.1016/S0360-3016(02)04477-2
|
[17]
|
K. Lehti?, V. Oikonen, S. Nyman, T. Gr?nroos, A. Roivainen, O. Eskola and H. Minn, “Quantifying Tumor Hypoxia with Fluorine-18 Fluoroerythronitroimidazole ([18F]FETNIM) and PET Using the Tumor to Plasma Ratio,” European Journal of Nuclear Medicine and Mo- lecular Imaging, Vol. 30, No. 1, 2003, pp. 101-108.
doi:10.1007/s00259-002-1016-x
|
[18]
|
R. Beck, B. R?per, J. M. Carlsen, M. C. Huisman, J. A. Lebschi, N. Andratschke, M. Picchio, M. Souvatzoglou, H. J. Machulla and M. Piert, “Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine,” Journal of Nuclear Medicine, Vol. 48, No. 6, 2007, pp. 973-980.
doi:10.2967/jnumed.106.038570
|
[19]
|
L. S. Ziemer, S. M. Evans, A. V. Kachur, A. L. Shuman, C. A. Cardi, W. T. Jenkins, J. S. Karp, A. Alavi, W. R. Jr. Dolbier and C. J. Koch, “Noninvasive Imaging of Tumor Hypoxia in Rats Using the 2-Nitroimidazole 18F-EF5,” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, No. 10, 2007, pp.1566-1575.
|
[20]
|
J. G. Rajendran, D. A. Mankoff, F. O’Sullivan, L. M. Peterson, D. L. Schwartz, E. U. Conrad, A. M. Spence, M. Muzi, D. G. Farwell and K. A. Krohn, “Hypoxia and Glucose Metabolism in Malignant Tumors: Evaluation by FMISO and FDG Positron Emission Tomography Imaging,” Clin. Cancer Res, Vol. 10, No. 7, 2004, pp. 2245-2252. doi:10.1158/1078-0432.CCR-0688-3
|
[21]
|
W. J. Koh, J. S. Rasey, M. L. Evans, J. R. Grierson, T. K. Lewellen, M. M. Graham, K. A. Krohn and T. W. Griffin, “Imaging of Hypoxia in Human Tumors with [F-18]Fluoromisonidazole,” International Journal of Radiation Oncology * Biology * Physics, Vol. 22, No. 1, 1992, pp. 199-212. doi:10.1016/0360-3016(92)91001-4
|
[22]
|
D. Thorwarth, S. M. Eschmann, F. Paulsen and M. Alber, “A Kinetic Model for Dynamic [18F]-Fmiso PET Data to Analyze Tumor Hypoxia,” Physics in Medicine and Biology, Vol. 50, No. 10, 2005, pp. 2209-2224.
doi:10.1088/0031-9155/50/10/002
|
[23]
|
P. Zanzonico, J. Campa, D. Polycarpe-Holman, G. Froster, R. Finn, S. Larson, J. Humm and C. Ling, “Ani- mal-Specific Positioning Molds for Registration of Re- peat Imaging Studies: Comparative microPET Imaging of F18-Labeled Fluoro-Deoxyglucose and Fluoro-Misonidazole in Rodent Tumors,” Nuclear Medicine and Biol- ogy, Vol. 33, No. 1, 2006, pp. 65-70.
doi:10.1016/j.nucmedbio.2005.07.011
|
[24]
|
A. Cherif, D. J. Yang, W. Tansey, E. E. Kim and S. Wallace, “Rapid Synthesis of 3-[18F]Fluoro-1-9-(2’-nitro-1’- imidazolyl)-2-propanol([18F]fluoromisonidazole),” Pharmaceutical Research, Vol. 11, No. 3, 1994, pp. 466-469. doi:10.1023/A:1018937709835
|
[25]
|
D. J. Yang, S. Wallace, A. Cherif, C. Li, M. B. Gretzer, E. E. Kim and D. A. Podoloff, “Development of F-18-Labled Fluoroerythronitroimidazole as a PET Agent for Imaging Tumor Hypoxia,” Radiology, Vol. 194, No. 3, pp. 795-800.
|
[26]
|
M. Zhang, M. Huang, C. Le, P. B. Zanzonico, F. Claus, K. S. Kolbert, K. Martin, C. C. Ling, J. A. Koutcher and J. L. Humm, “Accuracy and Reproducibility of Tumor Positioning during Prolonged and Multi-Modality Animal Imaging Studies,” Physics in Medicine and Biology, Vol. 53, No. 20, 2008, pp. 5867-5882.
doi:10.1088/0031-9155/53/20/021
|
[27]
|
W. O. Kermack and A. G. McKendrick, “Contributions to the Mathematical Theory oF Epidemics: IV. Analysis of Experimental Epidemics of the Virus Disease Mouse Ectromelia,” Journal of Hygiene, Vol. 37, No. 2, 1937, pp. 172-187. doi:10.1017/S0022172400034902
|
[28]
|
R. K. Jain and L. E. Gerlowski, “Extravascular Transport in Normal and Tumor Tissues,” Critical Reviews in On- cology/Hematology, Vol. 5, No. 2, 1986, pp. 115-170. Reviewdoi:10.1016/S1040-8428(86)80023-3
|
[29]
|
J. J. Casciari, M. M. Graham and J. S. Rasey, “A Modeling Approach for Quantifying Tumor Hypoxia with [F- 18]Fluoromisonidazole PET Time-Activity Data, Medical Physics, Vol. 22, No. 7, 1995, pp. 112-139.
doi:10.1118/1.597506
|
[30]
|
M. Bruehlmeier, U. Roelcke, P. A. Schubiger and S. M. Ametamey, “Assessment of Hypoxia and Perfusion in Human Brain Tumors Using PET with 18F-Fluoromi-sonidazole and 15O-H2O,” Journal of Nuclear Medicine, Vol. 45, No. 11, 2004, pp. 1851-1859.
|
[31]
|
W. Wang, J. C. Georgi, S. A. Nehmeh, M. Narayanan, T. Paulus, M., Bal, J. A. O’Donoghue, P. B. Zanzonico, C. R. Schmidtlein, N. Y. Lee and J. L. Humm, “Evaluation of a Compartmental Model for Estimating Tumor Hypoxia via FMISO Dynamic PET Imaging,” Physics in Medicine and Biology, Vol. 54, No. 10, 2009, pp. 3083-3099.
doi:10.1088/0031-9155/54/10/008
|
[32]
|
R. M. Bartlett, B. J. Beattie, M. Naryanan, J. C. Georgi, Q. Chen, S. D. Carlin, G. Roble, P. B. Zanzonico, M. Gonen, J. O’Donoghue, A. Fischer, J. L. Humm, “Image-Guided PO2 Probe Measurements Correlated with Parametric Images Derived from 18F-Fluoromisonidazole Small-Ani- mal PET Data in Rats”, Journal of Nuclear Medicine, Vol. 53, No. 10, 2012.
|